Expanded RAS: Refining the Patient Population
Cet article passe en revue les travaux récents sur l'intérêt de la recherche de mutations des gènes RAS pour la prise en charge des patients atteints d'un cancer colorectal
The era of precision medicine has changed the treatment paradigm for some cancers, but for others, the term precision is a stretch. New targets and therapies have broadened choices for patients with lung cancer or melanoma; however, in colorectal cancer (CRC), for example, the evolution of biomarkers has been primarily to inform whom not to treat rather than to identify the patients who will benefit from treatment. The refinements in CRC have been limiting rather than expansive; by broadening the definition of RAS mutations, fewer patients have multiple targeted options...
Journal of Clinical Oncology , article en libre accès, 2015